118 related articles for article (PubMed ID: 24518370)
21. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Drug Test Anal; 2012 Jun; 4(6):449-54. PubMed ID: 22447497
[TBL] [Abstract][Full Text] [Related]
22. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
23. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
Courlet P; Buclin T; Biollaz J; Mazzoni I; Rabin O; Guidi M
CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):469-481. PubMed ID: 35315251
[TBL] [Abstract][Full Text] [Related]
24. Urinary and blood concentrations of beta2-agonists in trained subjects: comparison between routes of use.
Pichon A; Venisse N; Krupka E; Pérault-Pochat MC; Denjean A
Int J Sports Med; 2006 Mar; 27(3):187-92. PubMed ID: 16541373
[TBL] [Abstract][Full Text] [Related]
25. High-dose inhaled salbutamol has no acute effects on aerobic capacity or oxygen uptake kinetics in healthy trained men.
Elers J; Mørkeberg J; Jansen T; Belhage B; Backer V
Scand J Med Sci Sports; 2012 Apr; 22(2):232-9. PubMed ID: 21083771
[TBL] [Abstract][Full Text] [Related]
26. Detection of main urinary metabolites of β2-agonists clenbuterol, salbutamol and terbutaline by liquid chromatography high resolution mass spectrometry.
Domínguez-Romero JC; García-Reyes JF; Martínez-Romero R; Martínez-Lara E; Del Moral-Leal ML; Molina-Díaz A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 923-924():128-35. PubMed ID: 23500357
[TBL] [Abstract][Full Text] [Related]
27. The salmeterol anomaly and the need for a urine threshold.
Jacobson GA; Hostrup M
Drug Test Anal; 2022 Jun; 14(6):997-1003. PubMed ID: 32314556
[TBL] [Abstract][Full Text] [Related]
28. Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
Schweizer C; Saugy M; Kamber M
Clin J Sport Med; 2004 Sep; 14(5):312-5. PubMed ID: 15377972
[TBL] [Abstract][Full Text] [Related]
29. Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes.
van Baak MA; de Hon OM; Hartgens F; Kuipers H
Int J Sports Med; 2004 Oct; 25(7):533-8. PubMed ID: 15459835
[TBL] [Abstract][Full Text] [Related]
30. Olodaterol and vilanterol detection in sport drug testing.
Chundela Z; Große J
Drug Test Anal; 2015; 7(11-12):980-2. PubMed ID: 26593301
[TBL] [Abstract][Full Text] [Related]
31. Urine concentrations of vilanterol and its metabolites, GSK932009 and GW630200, after inhalation of therapeutic and supratherapeutic doses.
Østergaard M; Jessen S; Hansen ESH; Backer V; Panchal T; Baldwin S; Daley-Yates P; Hostrup M
Drug Test Anal; 2023 May; 15(5):516-528. PubMed ID: 36610030
[TBL] [Abstract][Full Text] [Related]
32. Ultraperformance liquid chromatography tandem mass spectrometric method for direct quantification of salbutamol in urine samples in doping control.
Ventura R; Ramírez R; Monfort N; Segura J
J Pharm Biomed Anal; 2009 Dec; 50(5):886-90. PubMed ID: 19596537
[TBL] [Abstract][Full Text] [Related]
33. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
Wolfarth B; Wuestenfeld JC; Kindermann W
Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
[TBL] [Abstract][Full Text] [Related]
34. Detection of inhaled salbutamol in equine urine by ELISA and GC/MS2.
Eenoo PV; Delbeke FT
Biomed Chromatogr; 2002 Dec; 16(8):513-6. PubMed ID: 12474214
[TBL] [Abstract][Full Text] [Related]
35. Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Ther Drug Monit; 2011 Oct; 33(5):627-31. PubMed ID: 21912333
[TBL] [Abstract][Full Text] [Related]
36. Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box".
Cawley AT; Hine ER; Trout GJ; George AV; Kazlauskas R
Forensic Sci Int; 2004 Jul; 143(2-3):103-14. PubMed ID: 15240029
[TBL] [Abstract][Full Text] [Related]
37. Quantification and stability of salbutamol in human urine.
Forsdahl G; Gmeiner G
J Sep Sci; 2004 Jan; 27(1-2):110-4. PubMed ID: 15335066
[TBL] [Abstract][Full Text] [Related]
38. Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations.
Coll S; Monfort N; Matabosch X; Papakonstantinou K; Pérez-Mañá C; Mateus JA; Ventura R
Drug Test Anal; 2020 May; 12(5):629-636. PubMed ID: 31306564
[TBL] [Abstract][Full Text] [Related]
39. Effect of salbutamol on neuromuscular function in endurance athletes.
Decorte N; Bachasson D; Guinot M; Flore P; Levy P; Verges S; Wuyam B
Med Sci Sports Exerc; 2013 Oct; 45(10):1925-32. PubMed ID: 23559124
[TBL] [Abstract][Full Text] [Related]
40. Acute impact of inhaled short acting b2-agonists on 5 km running performance.
Dickinson J; Hu J; Chester N; Loosemore M; Whyte G
J Sports Sci Med; 2014 May; 13(2):271-9. PubMed ID: 24790479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
